Figure 3. YZ129 suppresses the growth of glioblastoma xenografts in vivo.

A. Representative bioluminescence images of U87-Luc xenografts. Nude mice were subcutaneously transplanted with U87-Luc GBM cells and treated with vehicle or YZ129 every day for 5 days at a dose of 2.5 μM/kg body weight. The tumor size was monitored each week using bioluminescence imaging.

B. Representative images of tumors dissected from vehicle-treated or YZ129-treated nude mice at week 3.

C. Tumor size was assessed by the weekly bioluminescence intensities in xenograft tumors and plotted relative to the bioluminescence at week 3 for the DMSO control group (mean ± SD, n = 6).

D. The volumes of tumor masses isolated from nude mice treated with DMSO or YZ129 (mean ± SD, n=6). Each dot represents the tumor volume from one mouse. ***P < 0.001 (Two-tailed Student’s t-test).

E. HE staining of the dissected subcutaneous xenograft tumor tissues from mice treated with vehicle (DMSO) or YZ129. Arrow, sign of karyopyknosis with nuclear chromatin condensation. Scale bars, 50 μm.

F. Representative images of immunohistochemical (IHC) staining of cell proliferation marker Ki67 and activated caspase 3 in GBM xenografts isolated from mice treated with vehicle or YZ129. Scale bars, 50 μm. Percentage of positive cells was scored from 4–6 random fields per tumor section. ***P < 0.001 (Two-tailed Student’s t-test).

See also Figure S2